AFP and hepatocellular carcinoma: AFP is the only serum biomarker currently measured in the clinical management of patients with HCC, but has a 30% false negative rate in HCC diagnosis and even worse performance in relapse prediction (Farinati et al. 2006; Mehta et al. 2017).